Список литературы

Поставить закладку

Rosenberg WM, Gray JA et al. Evidence based medicine: what it is and what it isn"t. BMJ 1996, January; 312 (7023): 71–72.
Федеральный закон от 21.11.2011 № 323-ФЗ (ред. от 03.04.2017) «Об основах охраны здоровья граждан в Российской Федерации».
Эпидемиологический словарь, 4-е издание. Под ред. Джона М. Ласта для Международной эпидемиологической ассоциации. М, 2009. 316 с.
Федеральное агентство по техническому регулированию и метрологии. Национальный стандарт Российской Федерации. ГОСТР 52379–2005. Надлежащая клиническая практика. Москва, 2005.
Федеральный закон от 12.04.2010 № 61-ФЗ (ред. от 03.07.2016) «Об обращении лекарственных средств».
Малая медицинская энциклопедия. М.: Медицинская энциклопедия, 1991—96 гг. [Электронный ресурс]. Режим доступа:http://dic.academic.ru/dic.nsf/enc_medicine/28878/Синдром.
Андреева Н. С, Реброва О. Ю, Зорин Н. А. и др. Системы оценки достоверности научных доказательств и убедительности рекомендаций: сравнительная характеристика и перспективы унификации. Медицинские технологии. Оценка и выбор. 2012. №. 4. С. 10–24.
Кухарчук В. В. и др. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации, VII пересмотр //Атеросклероз и дислипидемии. 2020. Т. 11. №. 1 (38).
Nordestgaard BG et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. //European heart journal. 2013. Vol. 34. №. 45. P. 3478–3490.
Yao Z. Human apolipoprotein C-III — a new intrahepatic protein factor promoting assembly and secretion of very low density lipoproteins. Cardiovasc Hematol Disord Drug Targets. 2012;12(2):133–140.
Sacks FM, Alaupovic P, Moye LA, et al. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation. 2000;102:1886–1892.
Hegele RA, Ginsberg HN, Chapman MJ et al. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol. 2014. 2(8): 655–666. doi:10.1016/S2213-8587(13)70191-8
Метельская В. А. и др. Анализ распространенности показателей, характеризующих атерогенность спектра липопротеидов, у жителей Российской Федерации (по данным исследования ЭССЕ-РФ) //Профилактическая медицина. 2016. Т. 19. №. 1. P. 15–23.
Caggiula AW et al. The multiple risk factor intervention trial (MRFIT): IV. Intervention on blood lipids //Preventive Medicine. 1981. Vol. 10. №. 4. P. 443–475.
Castelli WP. Epidemiology of triglycerides: A view from Framingham. Am J Cardiol. 1992. 70(19): H3–H9. doi:10.1016/0002-9149(92)91083-g
Carey VJ et al. Contribution of high plasma triglycerides and low high-density lipoprotein cholesterol to residual risk of coronary heart disease after establishment of low-density lipoprotein cholesterol control //The American journal of cardiology. 2010. Vol. 106. №. 6. P. 757–763.
Barter P, Gotto AM, LaRosa JC et al. HDL Cholesterol, Very Low Levels of LDL Cholesterol, and Cardiovascular Events. New England Journal of Medicine. 2007. 357(13): 1301–1310. doi:10.1056/nejmoa064278
Aguiar C et al. A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate–statin combination therapy //Atherosclerosis Supplements. 2015. Vol. 19. P. 1–12.
Prospective Studies Collaboration et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55 000 vascular deaths //The Lancet. 2007. Vol. 370. №. 9602. P. 1.
Catapano AL et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. // Eur Heart J. 2016. Vol. 37. №. 39. P. 2999–3058.
Holewijn S et al. Apolipoprotein B, non-HDL cholesterol and LDL cholesterol for identifying individuals at increased cardiovascular risk // Journal of internal medicine. 2010. Vol. 268. №. 6. P. 567–577.
Boekholdt SM et al. Association of LDL cholesterol, non–HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis // Jama. 2012. Vol. 307. №. 12. P. 1302–1309.
Langsted A, Nordestgaard BG. Nonfasting versus fasting lipid profile for cardiovascular risk prediction. Pathology. 2019. 51(2): 131–141. doi:10.1016/j.pathol.2018.09.062
Farukhi Z, Mora S. The Future of Low-Density Lipoprotein Cholesterol in an Era of Nonfasting Lipid Testing and Potent Low-Density Lipoprotein Lowering. Circulation. 2018. 137(1): 20–23. doi:10.1161/CIRCULATIONAHA.117.031857
Meijboom WB, Meijs MF, Schuijf JD et al. Diagnostic accuracy of 64-slice computed tomography coronary angiography: a prospective, multicenter, multivendor study. J Am Coll Cardiol. 2008. 52(25): 2135–2144. doi:10.1016/j.jacc.2008.08.058
Agatston AS, Janowitz WR, Hildner FJ et al. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990. 15(4): 827–832. doi:10.1016/0735-1097(90)90282-t
Serrano CV, de Mattos FR, Pitta FG et al. Association between Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratios and Coronary Artery Calcification Score among Asymptomatic Patients: Data from a Cross-Sectional Study. Mediators Inflamm. 2019. 2019: 1–8. doi:10.1155/2019/6513847
Piepoli MF et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice, (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR) // European heart journal. 2016. Vol. 37. №. 29. P. 231.
Mortensen MB, Falk E, Li D et al. Statin Trials, Cardiovascular Events, and Coronary Artery Calcification. JACC: Cardiovascular Imaging. 2018. 11(2): 221–230. doi:10.1016/j.jcmg.2017.01.029
McDermott MM, Kramer CM, Tian L et al. Plaque Composition in the Proximal Superficial Femoral Artery and Peripheral Artery Disease Events. JACC: Cardiovascular Imaging. 2017. 10(9): 1003–1012. doi:10.1016/j.jcmg.2016.08.012
Sillesen H, Sartori S, Sandholt B et al. Carotid plaque thickness and carotid plaque burden predict future cardiovascular events in asymptomatic adult Americans. European Heart Journal — Cardiovascular Imaging. 2017. 19(9): 1042–1050. doi:10.1093/ehj
Perrone-Filardi P, Achenbach S, Mohlenkamp S et al. Cardiac computed tomography and myocardial perfusion scintigraphy for risk stratification in asymptomatic individuals without known cardiovascular disease:, a position statement of the Working Group on Nuclear Cardiology and Cardiac CT of the European Society of Cardiology //European heart journal. 2011. Vol. 32. №. 16. P. 1986–1993.
Den Ruijter HM, Peters SAE, Anderson TJ et al. Common Carotid Intima-Media Thickness Measurements in Cardiovascular Risk Prediction. JAMA. 2012. 308(8): 796–803. doi:10.1001/jama.2012.9630
Inaba Y, Chen JA, Bergmann SR. Carotid plaque, compared with carotid intima-media thickness, more accurately predicts coronary artery disease events: a meta-analysis // Atherosclerosis. 2012. Vol. 220. №. 1. P. 128–133.
Lorenz MW et al. Carotid intima-media thickness progression to predict cardiovascular events in the general population (the PROG-IMT collaborative project): a meta-analysis of individual participant data // The Lancet. 2012. Vol. 379. №. 9831. P. 2053–2062.
Pletcher MJ et al. Using the coronary artery calcium score to predict coronary heart disease events: a systematic review and meta-analysis // Archives of internal medicine. 2004. Vol. 164. №. 12. P. 1285–1292.
Akioyamen LE et al. Risk factors for cardiovascular disease in heterozygous familial hypercholesterolemia: A systematic review and meta-analysis // Journal of clinical lipidology. 2019. Vol. 13. №. 1. P. 15–30.
Cannon C. P et al. Ezetimibe added to statin therapy after acute coronary syndromes // New England Journal of Medicine. 2015. Vol. 372. №. 25. P. 2387–2397.
Trialists CT et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials // The Lancet. 2015. Vol. 385. №. 9976. P. 1397–1405.
Sabatine MS et al. Evolocumab and clinical outcomes in patients with cardiovascular disease // New England Journal of Medicine. 2017. Vol. 376. №. 18. P. 1713–1722.
Jukema JW et al. ODYSSEY OUTCOMES Committees and Investigators. Alirocumab in patients with polyvascular disease and recent acute coronary syndrome: ODYSSEY OUTCOMES trial // J Am Coll Cardiol. 2019. Vol. 74. №. 9. P. 1167–1176.
Trialists CT et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials // The Lancet. 2012. Vol. 380. №. 9841. P. 581–590.
Santos RD et al. Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel // The lancet Diabetes & endocrinology. 2016. Vol. 4. №. 10. P. 850–861.
Eckel RH, Jakicic JM, Ard JD et al. 2013 AHA/ACC Guideline on Lifestyle Management to Reduce Cardiovascular Risk. Circulation. 2013. 129(25 suppl 2): S76–S99. doi:10.1161/01.cir.0000437740.48606.d1
de Lorgeril M, Salen P, Martin J-L et al. Mediterranean Diet, Traditional Risk Factors, and the Rate of Cardiovascular Complications After Myocardial Infarction. Circulation. 1999. 99(6): 779–785. doi:10.1161/01.cir.99.6.779.
Estruch R, Ros E, Salas-Salvado J, et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts. N Engl J Med. 2018. 378(25): e34. doi:10.1056/NEJMoa1800389.
Mozaffarian D, Lemaitre RN, King IB et al. Plasma Phospholipid Long-Chain ω-3 Fatty Acids and Total and Cause-Specific Mortality in Older Adults. Ann Intern Med. 2013. 158(7): 515–525. doi:10.7326/0003-4819-158-7-201304020-00003
Lu Z, Kou W, Du B, et al. Effect of Xuezhikang, an Extract From Red Yeast Chinese Rice, on Coronary Events in a Chinese Population With Previous Myocardial Infarction. Am J Cardiol. 2008. 101(12): 1689–1693. doi:10.1016/j.amjcard.2008.02.056
Li Y, Jiang L, Jia Z, et al. A Meta-Analysis of Red Yeast Rice: An Effective and Relatively Safe Alternative Approach for Dyslipidemia. PLoS One. 2014. 9(6): e98611. doi:10.1371/journal.pone.0098611
Mach F, Baigent C, Catapano A.L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019. doi:10.1093/eurheartj/ehz455
Taylor F, Huffman MD, Macedo AF et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews. 2013. doi:10.1002/14651858.cd004816.pub5
Sever PS, Dahlöf B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial, Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. The Lancet. 2003. 361(9364): 1149–1158. doi:10.1016/s0140-6736(03)12948-0
Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. The Lancet, 2004. 364(9435): 685–696. doi:10.1016/s0140-6736(04)16895-5
Schwartz GG. Effects of Atorvastatin on Early Recurrent Ischemic Events in Acute Coronary Syndromes «SUBTITLE»The MIRACL Study: A Randomized Controlled Trial «SUBTITLE». JAMA. 2001. 285(13): 1711. doi:10.1001/jama.285.13.1711
Cannon CP, Braunwald E, McCabe CH et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004. 350(15): 1495–1504. doi:10.1056/NEJMoa040583
Patti G, Pasceri V, Colonna G et al. Atorvastatin Pretreatment Improves Outcomes in Patients With Acute Coronary Syndromes Undergoing Early Percutaneous Coronary Intervention. J Am Coll Cardiol. 2007. 49(12): 1272–1278. doi:10.1016/j.jacc.2007.02.025
Shepherd J, Kastelein JJ, Bittner V et al. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol. 2008. 51(15): 1448–1454. doi:10.1016/j.jacc.2007.11.072
Athyros VG, Papageorgiou AA, Mercouris BR et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus "usual" care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease, Evaluation (GREACE) study. Curr Med Res Opin. 2002. 18(4): 220–228. doi:10.1185/030079902125000787
Amarenco P, Bogousslavsky J, Callahan A 3rd et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006. 355(6): 549–559. doi:10.1056/NEJMoa061894
Newman CB, Palmer G, Silbershatz H et al. Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients. Am J Cardiol. 2003. 92(6): 670–676. doi:10.1016/s0002-9149(03)00820-8
Boekholdt SM, Hovingh GK, Mora S et al. Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events. J Am Coll Cardiol. 2014. 64(5): 485–494. doi:10.1016/j.jacc.2014.02.615
Fruchart JC, Duriez P. Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. Drugs of Today. 2006. 42(1): 39. doi:10.1358/dot.2006.42.1.963528.
Keating GM, Croom KF. Fenofibrate. Drugs. 2007. 67(1): 121–153. doi:10.2165/00003495-200767010-00013.
Group SC. Study of Heart and Renal Protection (SHARP): Randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. Am Heart J. 2010. 160(5): 785–794.e710. doi:10.1016/j.ahj.201.
Abifadel M, Varret M, Rabès J-P et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003. 34(2): 154–156. doi:10.1038/ng1161
Norata GD, Tibolla G, Catapano AL. Targeting PCSK9 for Hypercholesterolemia. Annual Review of Pharmacology and Toxicology. 2014. 54(1): 273–293. doi:10.1146/annurev-pharmtox-011613-140025
Giugliano RP et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial //The Lancet. 2017. Vol. 390. №. 10106. P. 1962–1971.
Bhatt DL et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia //New England Journal of Medicine. 2019. Vol. 380. №. 1. P. 11–22.
Brugts JJ et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials // Bmj. 2009. Vol. 338.
Mills EJ et al. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients // Journal of the American College of Cardiology. 2008. Vol. 52. №. 22. P. 1769–1781.
Moriarty PM et al. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial // Journal of clinical lipidology. 2015. Vol. 9. №. 6. P. 758–769.
Nissen SE et al. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial // Jama. 2016. Vol. 315. №. 15. P. 1580–1590.
Schreml J, Gouni-Berthold I. Role of anti-PCSK9 antibodies in the treatment of patients with statin intolerance // Current medicinal chemistry. 2018. Vol. 25. №. 13. P. 1538–1548.
Landmesser U et al. European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk //, European Heart Journal. 2017. Vol. 38. №. 29. P. 2245–2255.
Ridker PM et al. Cardiovascular efficacy and safety of bococizumab in high-risk patients // New England Journal of Medicine. 2017. Vol. 376. №. 16. P. 1527–1539.
Vallejo-Vaz AJ et al. Triglyceride-rich lipoprotein cholesterol and risk of cardiovascular events among patients receiving statin therapy in the TNT trial //Circulation. 2018. Vol. 138. №. 8. P. 770–781.
Chapman MJ et al. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk //Pharmacology & therapeutics. 2010. Vol. 126. №. 3. P. 314–345.
ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus // New England Journal of Medicine. 2010. Vol. 362. №. 17. P. 1563–1574.
FIELD Study Investigators et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial // The Lancet. 2005. Vol. 366. №. 9500. P. 1849–1861.
Doll R. Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis // Lancet. 2008. Vol. 371. №. 9607. P. 117–125.
Nicholls SJ et al. Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 intravascular ultrasound trials // Journal of the American College of Cardiology. 2008. Vol. 52. №. 4. P. 255–262.
Laing SP et al. Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes //Diabetologia. 2003. Vol. 46. №. 6. P. 760–765.
Giugliano RP et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) //, Circulation. 2018. Vol. 137. №. 15. P. 1571–1582.
Zinman B, Wanner C, Lachin JM et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine. 2015. 373(22): 2117–2128.
Marso SP et al. Liraglutide and cardiovascular outcomes in type 2 diabetes //New England Journal of Medicine. 2016. Vol. 375. № 4. P. 311–322.
Marso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes //N Engl J Med. 2016. Vol. 375. P. 1834–1844.
McGuire DK et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis // JAMA cardiology. 2020.
88. McGuire DK et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis // JAMA cardiology. 2020.
UK Prospective Diabetes Study (UKPDS) Group et al. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) // The Lancet. 1998. Vol. 352. №. 9131. P. 854–865.
Franczyk-Skora B et al. Acute coronary syndromes in patients with chronic kidney disease // Current vascular pharmacology. 2013. Vol. 11. №. 5. P. 758–767.
Loncar G et al. Impact of renal failure on all-cause mortality and other outcomes in patients treated by percutaneous coronary intervention //Archives of Cardiovascular Diseases. 2015. Vol. 108. №. 11. P. 554–562.
Herrington W et al. Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials //Lancet Diabetes and Endocrinology. 2016. Vol. 4. №. 10.
Baigent C et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial // The Lancet. 2011. Vol. 377. №. 9784. P, 2181–2192.
Barylski M et al. Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy—a meta-analysis of 11 randomized controlled trials involving 21,295 participants // Pharmacological research. 2013. Vol. 72. P. 35–44.
Palmer SC et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis // Cochrane Database of Systematic Reviews. 2014. №. 5.
Sun L et al. Meta-analysis of statin therapy in maintenance dialysis patients // Renal Failure. 2015. Vol. 37. №. 7. P. 1149–1156.
Green D, Ritchie JP, Kalra PA. Meta-analysis of lipid-lowering therapy in maintenance dialysis patients // Nephron Clinical Practice. 2013. Vol. 124. №. 3–4. P. 209–217.
Lin YC et al. Effects and Safety of Statin and Ezetimibe Combination Therapy in Patients with Chronic Kidney Disease: A Systematic Review and Meta-Analysis // Clinical Pharmacology & Therapeutics. 2020.
Wanner C et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis // New England Journal of Medicine. 2005. Vol. 353. №. 3. P. 238–248.
Fellström BC et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis // New England Journal of Medicine. 2009. Vol. 360. №. 14. P. 1395–1407.
de Lemos JA et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial // Jama. 2004. Vol. 292. №. 11. P. 1307–1316.
Ray KK et al. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial // Journal of the American College of Cardiology. 2005. Vol. 46. №. 8. P. 1405–1410.
Schwartz GG et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial // Jama. 2001. Vol. 285. №. 13. P. 1711–1718.
Koskinas KC et al. Evolocumab for early reduction of LDL cholesterol levels in patients with acute coronary syndromes (EVOPACS) // Journal of the American College of Cardiology. 2019. Vol. 74. №. 20. P. 2452–2462.
Trankle CR et al. Alirocumab in acute myocardial infarction: results from the Virginia commonwealth university alirocumab response trial (VCU-AlirocRT) // Journal of cardiovascular pharmacology. 2019. Vol. 74. №. 3. P. 266–269.
Armitage J et al. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials // The Lancet. 2019. Vol. 393. №. 10170. P. 407–415.
Taskinen MR et al. Adverse effects of fructose on cardiometabolic risk factors and hepatic lipid metabolism in subjects with abdominal obesity // Journal of internal medicine. 2017. Vol. 282. №. 2. P. 187–201.
Look AHEAD Research Group. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes // New England journal of medicine. 2013. Vol. 369. №. 2. P. 145–154.
Batsis JA et al. Weight loss interventions in older adults with obesity: a systematic review of randomized controlled trials since 2005 // Journal of the American Geriatrics Society. 2017. Vol. 65. №. 2. P. 257–268.
Khader YS et al. Oral contraceptives use and the risk of myocardial infarction: a meta-analysis // Contraception. 2003. Vol. 68. №. 1. P. 11–17.
Shufelt CL, Merz CNB. Contraceptive hormone use and cardiovascular disease // Journal of the American College of Cardiology. 2009. Vol. 53. №. 3. P. 221–231.
Manson JAE et al. Estrogen plus progestin and the risk of coronary heart disease // New England Journal of Medicine. 2003. Vol. 349. №. 6. P. 523–534.
Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack // New England Journal of Medicine. 2006. Vol. 355. №. 6. P. 549–559.
Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention // The Lancet Neurology. 2009. Vol. 8. №. 5. P. 453–463.
Chan K et al. Effect of Lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial // Circulation. 2010. Vol. 121. №. 2. P. 306–314.
Cowell SJ et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis // New England Journal of Medicine. 2005. Vol. 352. №. 23. P. 2389–2397.
Dichtl W et al. Prognosis and risk factors in patients with asymptomatic aortic stenosis and their modulation by atorvastatin (20 mg) // The American journal of cardiology. 2008. Vol. 102. №. 6. P. 743–748.
Rossebø AB et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis // New England journal of medicine. 2008. Vol. 359. №. 13. P. 1343–1356.
Kelley GA, Kelley KS, Tran ZV. Walking, lipids, and lipoproteins: a meta-analysis of randomized controlled trials // Preventive medicine. 2004. Vol. 38. №. 5. P. 651–661.
Hardman AE. Physical activity, obesity and blood lipids // International Journal of Obesity. 1999. Vol. 23. №. 3. P. S64–S71.
Tran ZV et al. The effects of exercise on blood lipids and lipoproteins: a meta-analysis of studies // Med Sci Sports Exerc. 1983. Vol. 15. №. 5. P. 393–402.
Mozaffarian D, Micha R, Wallace S. Effects on coronary heart disease of increasing polyunsaturated fat in place of saturated fat: a systematic review and meta-analysis of randomized controlled trials // PLoS Med. 2010. Vol. 7. №. 3. P. e1000252.
Mozaffarian D, Aro A, Willett W. C. Health effects of trans-fatty acids: experimental and observational evidence // European journal of clinical nutrition. 2009. Vol. 63. №. 2. P. S5–S21.
Clifton P. M, Keogh J. B. A systematic review of the effect of dietary saturated and polyunsaturated fat on heart disease // Nutrition, Metabolism and Cardiovascular Diseases. 2017. Vol. 27. №. 12. P. 1060–1080.
Brown L et al. Cholesterol-lowering effects of dietary fiber: a meta-analysis // The American journal of clinical nutrition. 1999. Vol. 69. №. 1. P. 30–42.
Hollænder PLB, Ross AB, Kristensen M. Whole-grain and blood lipid changes in apparently healthy adults: a systematic review and meta-analysis of randomized controlled studies // The American journal of clinical nutrition. 2015. Vol. 102. №. 3. P. 556–572.
Gylling H et al. Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease // Atherosclerosis. 2014. Vol. 232. №. 2. P. 346–360.
Musa-Veloso K et al. A comparison of the LDL-cholesterol lowering efficacy of plant stanols and plant sterols over a continuous dose range: results of a meta-analysis of randomized, placebo-controlled trials // Prostaglandins, Leukotrienes and Essential Fatty Acids. 2011. Vol. 85. №. 1. P. 9–28.
Poli A et al. Nutraceuticals and functional foods for the control of plasma cholesterol levels. An intersociety position paper // Pharmacological research. 2018. Vol. 134. P. 51–60.
Li Y et al. A meta-analysis of red yeast rice: an effective and relatively safe alternative approach for dyslipidemia // PloS one. 2014. Vol. 9. №. 6. P. e98611.
Nordmann AJ et al. Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials // Archives of internal medicine. 2006. Vol. 166. №. 3. P. 285–293.
Zomer E et al. Interventions that cause weight loss and the impact on cardiovascular risk factors: a systematic review and meta-analysis // Obesity reviews. 2016. Vol. 17. №. 10. P. 1001–1011.
Berger S et al. Dietary cholesterol and cardiovascular disease: a systematic review and meta-analysis // The American journal of clinical nutrition. 2015. Vol. 102. №. 2. P. 276–294.
Griffin JD, Lichtenstein AH. Dietary cholesterol and plasma lipoprotein profiles: randomized controlled trials // Current nutrition reports. 2013. Vol. 2. №. 4. P. 274–282.
Shaw K et al. Exercise for overweight or obesity. Cochrane Database Syst Rev 2006; CD003817. 2013.
Droste DW et al. A daily glass of red wine associated with lifestyle changes independentlyimproves blood lipids in patients with carotid arteriosclerosis: results from arandomized controlled trial // Nutrition journal. 2013. Vol. 12. №. 1. P. 147.
Rimm EB et al. Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors // Bmj. 1999. Vol. 319. №. 7224. P. 1523–1528.
Yu-Poth S et al. Effects of the National Cholesterol Education Program"s Step I and Step II dietary intervention programs on cardiovascular disease risk factors: a meta-analysis // The American journal of clinical nutrition. 1999. Vol. 69. №. 4. P. 632–646.
Santos FL et al. Systematic review and meta-analysis of clinical trials of the effects of low carbohydrate diets on cardiovascular risk factors // Obesity Reviews. 2012. Vol. 13. №. 11. P. 1048–1066.
Rivellese AA et al. Effects of dietary saturated, monounsaturated and n-3 fatty acids on fasting lipoproteins, LDL size and post-prandial lipid metabolism in healthy subjects // Atherosclerosis. 2003. Vol. 167. №. 1. P. 149–158.
Wei MY, Jacobson TA. Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: a systematic review and meta-analysis // Current atherosclerosis reports. 2011. Vol. 13. №. 6. P. 474–483.
Kelishadi R, Mansourian M, Heidari-Beni M. Association of fructose consumption and components of metabolic syndrome in human studies: a systematic review and meta-analysis // Nutrition. 2014. Vol. 30. №. 5. P. 503–510.
Stanhope KL et al. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans // The Journal of clinical investigation. 2009. Vol. 119. №. 5. P. 1322–1334.
Gayet-Boyer C et al. Is there a linear relationship between the dose of ruminant trans-fatty acids and cardiovascular risk markers in healthy subjects: results from a systematic review and meta-regression of randomised clinical trials // British Journal of Nutrition. 2014. Vol. 112. №. 12. P. 1914–1922.
Kelley GA, Kelley KS. Impact of progressive resistance training on lipids and lipoproteins in adults: a meta-analysis of randomized controlled trials // Preventive medicine. 2009. Vol. 48. №. 1. P. 9–19.
Kastorini CM et al. The effect of Mediterranean diet on metabolic syndrome and its components: a meta-analysis of 50 studies and 534,906 individuals // Journal of the American college of cardiology. 2011. Vol. 57. №. 11. P. 1299–1313.
Maeda K, Noguchi Y, Fukui T. The effects of cessation from cigarette smoking on the lipid and lipoprotein profiles: a meta-analysis // Preventive medicine. 2003. Vol. 37. №. 4. P. 283–290.
Mark L et al. Effects of ezetimibe on lipids and lipoproteins in patients with hypercholesterolemia and different apolipoprotein E genotypes // Current medical research and opinion. 2007. Vol. 23. №. 7. P. 1541–1548.
Li YH et al. 2017 Taiwan lipid guidelines for high risk patients // Journal of the Formosan Medical Association. 2017. Vol. 116. №. 4. P. 217–248.
Robinson JG et al. Eradicating the burden of atherosclerotic cardiovascular disease by lowering apolipoprotein B lipoproteins earlier in life // Journal of the American Heart Association. 2018. Vol. 7. №. 20. P. e009778.
Wilson DP et al. Use of Lipoprotein (a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association // Journal of clinical lipidology. 2019. Vol. 13. №. 3. P. 374–392.
Мешков А. Н. и др. Распределение показателей липидного спектра у мужчин и женщин трудоспособного возраста в Российской Федерации: результаты исследования эссе-РФ за 2012–2014 гг. // Кардиоваскулярная терапия и профилактика. 2017. Vol. 16. № 4. C. 62–67.
Болезни сердца по Браунвальду: руководство по сердечно-сосудистой медицине / под ред. П. Либби и др.; пер. с англ. под общ. ред. Р. Г. Оганова. В 4 т. Том 1. М.: Логосфера, 2012. 596 с.: ил.; 21,6 см. Перевод изд. Braunwald’s heart disease: a textbook of cardiovascular medicine, Peter Libby et al, 8th ed.
The Merck manual of diagnosis and therapyed. MH.Beers [et. al]. 17th ed. XXXIII, 2833 p.: il. Index.: p. 2657–2833. ISBN 0911910-10-7.
Lawler PR et al. Real-world risk of cardiovascular outcomes associated with hypertriglyceridaemia among individuals with atherosclerotic cardiovascular disease and potential eligibility for emerging therapies // Eur Heart J. 2020 Jan 1;41(1):86–94.
Liu J et al. Effects of blood triglycerides on cardiovascular and all-cause mortality: a systematic review and meta-analysis of 61 prospective studies // Lipids in health and disease. 2013. Vol. 12. №. 1. P. 1–11.
Kosmas CE, Estrella AM, Sourlas A et al. Inclisiran: A New Promising Agent in the Management of Hypercholesterolemia.
Levin AA. Treating disease ath the RNA levek with oligonucleotides. NEJM 2019;380:57–70.
Tsouka AN, Tellis CC, Tseplis AD. Pharmacology of PCK9 Inhibitors: current status and future perspectives. Current Pharmaceutical Design 2018;24:3622–3633.
Wang N, Tall AR. New approach to PCSK9 therapeutics. NEJM 2017; 376:41–51.
Ray KK, Phill M, Scot Wright R et al. Two phase 3 trials of Inclisiran in patients with elevated LDL cholesterol. NEJM 2020;382:1507–1519
Raal JF, Kallend D, Ray KK et al. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. NEJM 2020; 382:1520–1530.
Marston NA, Giugliano RP, Im K, Silverman MG, O"Donoghue ML, Wiviott SD, Ference BA, Sabatine MS. Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials. Circulation. 2019 Oct 15;140(16):1308–1317.
Rohit D, Shankar J. Comparative Study of Atorvastatin and Rosuvastatin in Combination with Fenofibrate in mixed Hyperlipidemia. Int J Pharmacol and Clin Sci. 2016;5(1):25–31.
Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. American Journal of Medicine 2007; 120(8): 713–719.
Baumgartner A, Drame K, Geutjens S, Airaksinen M (2020). Does the Polypill Improve Patient Adherence Compared to Its Individual Formulations? A Systematic Review. Pharmaceutics, 12(2), 190.
Cholesterol Treatment Trialists Collaboration, Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C. Efficacy of cholesterol lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008;371:117–125.
Bouzidi N et al. Effects of omega-3 polyunsaturated fatty-acid supplementation on redox status in chronic renal failure patients with dyslipidemia // Journal of renal nutrition. 2010. Vol. 20. №. 5. P. 321–328.
Svensson M et al. The effect of n-3 fatty acids on plasma lipids and lipoproteins and blood pressure in patients with CRF // American journal of kidney diseases. 2004. Vol. 44. №. 1. P. 77–83
Li WL et al. Dietary Omega-3 Fatty Acid Intake and Mortality in CKD Population: A 1999–2014 NHANES Analysis // American Journal of Nephrology. 2021. P. 1–10
Navarese EP, Kowalewski M, Andreotti F, van Wely M, Camaro C, Kolodziejczak M, Gorny B, Wirianta J, Kubica J, Kelm M, de Boer MJ, Suryapranata H. Meta-analysis of time-related benefits of statin therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Am J Cardiol 2014;113:1753_1764.
Visseren FLJ et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021 Sep 7;42(34):3227–3337.
Anthonisen NR et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial // Ann Intern Med. 2005. Vol. 142. № 4. P. 233–239.
Hughes JR et al. Antidepressants for smoking cessation // Cochrane Database Syst Rev. 2007. № 1. P. CD000031.
Lindson N et al. Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation // Cochrane Database Syst Rev. 2019. Vol. 4. № 4. P. CD013308.
Hu Y et al. Smoking Cessation, Weight Change, Type 2 Diabetes, and Mortality. // N Engl J Med. 2018. Vol. 379. № 7. P. 623–632.
Kavousi M et al. Electronic cigarettes and health with special focus on cardiovascular effects: position paper of the European Association of Preventive Cardiology (EAPC) // Eur J Prev Cardiol. 2020. 2047487320941993.
Powell K. E. et al. The Scientific Foundation for the Physical Activity Guidelines for Americans, 2nd Edition // J Phys Act Health. 2018. P. 1–11.
Hupin D et al. Even a low-dose of moderate-to-vigorous physical activity reduces mortality by 22% in adults aged >/=60 years: a systematic review and meta-analysis // Br J Sports Med. 2015. Vol. 49. № 19. P. 1262–1267.
Sacks FM et. al. American Heart Association. Dietary Fats and Cardiovascular Disease: A Presidential Advisory From the American Heart Association // Circulation. 2017. Vol. 136. № 10. P. e1e23.
He FJ et. al. Salt Reduction to Prevent Hypertension and Cardiovascular Disease: JACC State-of-the-Art Review // J Am Coll Cardiol. 2020. Vol. 75. № 6. P. 632–647.
World Health Organization. A healthy diet sustainably produced. https://apps.who.int/iris/bitstream/handle/10665/278948/WHO-NMH-NHD-18.12-eng.pdf? ua=1 (21 July 2020)
Zhong VW et. al. Associations of Processed Meat, Unprocessed Red Meat, Poultry, or Fish Intake With Incident Cardiovascular Disease and AllCause Mortality // JAMA Intern Med. 2020. Vol. 180. № 6. P.503–512.
World Health Organization. Guideline: sugars intake for adults and children. https://www.who.int/publications/i/item/9789241549028 (21 July 2020).
Wood AM et. al. Emerging Risk Factors Collaboration/EPIC-CVD/UK Biobank Alcohol Study Group. Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies // Lancet. 2018. Vol. 391. № 10129. P. 1513–1523.
Wing RR et. al. Association of Weight Loss Maintenance and Weight Regain on 4-Year Changes in CVD Risk Factors: the Action for Health in Diabetes (Look AHEAD) Clinical Trial // Diabetes Care. 2016. Vol. 39 № 12. P. 1345–1355.
Cardoso L et. al. Short- and long-term mortality after bariatric surgery: A systematic review and meta-analysis // Diabetes Obes Metab. 2017. Vol. 19. № 9. P. 1223–1232.
Sattar N. et. al. HbA1c in type 2 diabetes diagnostic criteria: addressing the right questions to move the field forwards // Diabetologia. 2012. Vol. 55. № 6. P. 1564–1567.
ADVANCE Collaborative Group et. al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes // N Engl J Med. 2008. Vol. 358. № 24. P. 2560–2572.
Ettehad D et. al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis // Lancet. 2016. Vol. 387. № 10022. P. 957–967.
SPRINT Research Group et. al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control // N Engl J Med. 2015. Vol. 373. № 22. P. 2103–2116.
Williamson JD et. al. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged >/=75 Years: A Randomized Clinical Trial // JAMA. 2016. Vol. 315. № 24. P. 2673–2682.
Thomopoulos C et. al. Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels — updated overview and meta-analyses of randomized trials // J Hypertens. 2016. Vol. 34. № 4. P. 613–622.
Antithrombotic Trialists’ (ATT) Collaboration et. al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials // Lancet. 2009. Vol. 373. № 9678. P. 1849–1860.
Cosentino F et. al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD // Eur Heart J. 2020. Vol. 41. № 2. P. 255–323.
Armenian SH et. al. Cardiovascular Disease Among Survivors of Adult-Onset Cancer: A Community-Based Retrospective Cohort Study // J Clin Oncol. 2016. Vol. 34. № 10. P. 1122–1130.
Chen W et. al. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis // Lancet Respir Med. 2015. Vol. 3. № 8. P. 631–639.
Ogdie Aet. al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study // Ann Rheum Dis. 2015. Vol. 74. № 2. P. 326–332.
Badran M et. al. Epidemiology of Sleep Disturbances and Cardiovascular Consequences // Can J Cardiol. 2015. Vol. 31. № 7. P. 873–879.
Zhao B et. al. Does erectile dysfunction independently predict cardiovascular events? It"s time to act on the evidence // Eur J Prev Cardiol. 2018. Vol. 25. № 12. P. 1307–1311.
Visseren FLJ et al, ESC National Cardiac Societies; ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice // Eur Heart J. 2021. Vol. 42(34). P. 3227–3337
Приказ Министерства здравоохранения РФ от 29 марта 2019 г. N 173н «Об утверждении порядка проведения диспансерного наблюдения за взрослыми».
Amarenco P, Kim JS, Labreuche J, Charles H, Abtan J, Béjot Y et al. A comparison of two LDL cholesterol targets after ischemic stroke. N Engl J Med. 2020;382(1):9. doi:10.1056/NEJMoa1910355
Cholesterol Treatment Trialists Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a metaanalysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:16701681
Cholesterol Treatment Trialists Collaboration, Fulcher J, O’Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, Simes J, Collins R, Kirby A, Colhoun H, Braunwald E, La Rosa J, Pedersen TR, Tonkin A, Davis B, Sleight P, Franzosi MG, Baigent C, Keech A. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials.Lancet2015;385:13971405
Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA et al; ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med.2018;379:2097–2107. doi:10.1056/NEJMoa1801174
Weng TC, Yang YH, Lin SJ, Tai SH. A systematic review and meta-analysis on the therapeutic equivalence of statins. J Clin Pharm Ther. 2010 Apr;35(2):139–51. doi:10.1111/j.1365-2710.2009.01085.x. PMID: 20456733
Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388:2532-61
Group HPSC. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg. 2007;45:645–54.
Nanna MG, Navar AM, Wang TY, Mi X, Virani SS, Louie MJ, Lee LV, Goldberg AC, Roger VL, Robinson J, Peterson ED. Statin Use and Adverse Effects Among Adults >75 Years of Age: Insights From the Patient and Provider Assessment of Lipid Management (PALM) Registry. J Am Heart Assoc. 2018 May 8;7(10):e008546. doi:10.1161/JAHA.118.008546. PMID: 29739801; PMCID: PMC6015311.
Yang Z, Edwards D, Massou E, Saunders CL, Brayne C, Mant J. Statin use and high-dose statin use after ischemic stroke in the UK: a retrospective cohort study. Clin Epidemiol. 2019 Jun 28;11:495–508. doi:10.2147/CLEP.S201983. PMID: 31388316; PMCID: PMC6607979.
Bohula EA, Wiviott SD, Giugliano RP, Blazing MA, Park JG, Murphy SA, White JA, Mach F, Van de Werf F, Dalby AJ, et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation.2017;136:2440–2450. doi:10.1161/CIRCULATIONAHA.117.029095
Chiavaroli L, Nishi SK, Khan TA, Braunstein CR, Glenn AJ, Mejia SB, RahelićD, Kahleová H, Salas-Salvadó J, Jenkins DJA, et al. Portfolio dietary pattern and cardiovascular disease: a systematic review and metaanalysis of controlled trials. Prog Cardiovasc Dis.2018;61:43–53. doi:10.1016/j.pcad.2018.05.004
Benner JS, Tierce JC, Ballantyne CM, Prasad C, Bullano MF, Willey VJ, Erbey J, Sugano DS. Follow-up lipid tests and physician visits are associated with improved adherence to statin therapy. Pharmacoeconomics. 2004;22(suppl 3):13–23. doi:10.2165/00019053-200422003-00003
Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesaniemi YA, Sullivan D, Hunt D, Colman P, d’Emden M, Whiting M, Ehnholm C, Laakso M; FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet2005;366:18491861
Aim-High Investigators, Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.N Engl J Med2011;365:22552267.
Group HTC, Landray MJ, Haynes R, Hopewell JC, Parish S, Aung T, Tomson J, Wallendszus K, Craig M, Jiang L, Collins R, Armitage J. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med2014;371:203–212.
Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987 Nov 12;317(20):1237–45. doi:10.1056/NEJM198711123172001. PMID: 3313041
Lipids and lipoproteins in symptomatic coronary heart disease. Distribution, intercorrelations, and significance for risk classification in 6,700 men and 1,500 women. The Bezafibrate Infarction Prevention (BIP) Study Group, Israel. Circulation1992;86:839848
Defesche JC, Gidding SS, Harada-Shiba M et al. Familial hypercholesterolaemia. Nat Rev Dis Primers. 2017 Dec 7;3:17093. doi:10.1038/nrdp.2017.93.
Ershova AI, Meshkov AN, Bazhan SS et al. The prevalence of familial hypercholesterolemia in the West Siberian region of the Russian Federation: A substudy of the ESSE-RF. PLoS One. 2017; 12 (7): e0181148.
Cuchel M, Bruckert E, Ginsberg HN et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J. 2014 Aug 21;35(32):2146–57. doi:10.1093/eurheartj/ehu274
Civeira F; International Panel on Management of Familial Hypercholesterolemia. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis. 2004 Mar;173(1):55–68. doi:10.1016/j.atherosclerosis.2003.11.010
Кухарчук В. В, Малышев П. П., Мешков А. Н. Семейная гиперхолестеринемия: современные аспекты диагностики, профилактики и терапии. Кардиология. 2009;49(1):76–83.
Yuan G, Wang J, Hegele RA. Heterozygous familial hypercholesterolemia: an underrecognized cause of early cardiovascular disease. CMAJ. 2006 Apr 11;174(8):1124–9. doi:10.1503/cmaj.051313
Vuorio A, Docherty KF, Humphries SE et al. Statin treatment of children with familial hypercholesterolemia — trying to balance incomplete evidence of long-term safety and clinical accountability: are we approaching a consensus? Atherosclerosis. 2013 Feb;226(2):315–20. doi:10.1016/j.atherosclerosis.2012.10.032
Hopkins PN, Toth PP, Ballantyne CM, Rader DJ. Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011 Jun;5(3 Suppl):S9–17. doi:10.1016/j.jacl.2011.03.452
Myant NB. Familial defective apolipoprotein B-100: a review, including some comparisons with familial hypercholesterolaemia. Atherosclerosis. 1993 Dec;104(1–2):1–18. doi:10.1016/0021-9150(93)90171-p
Meriño-Ibarra E, Castillo S, Mozas P et al. Screening of APOB gene mutations in subjects with clinical diagnosis of familial hypercholesterolemia. Hum Biol. 2005 Oct;77(5):663–73. PMID: 16596945.
Мешков А. Н, Ершова А. И, Щербакова Н. В. и др. Фенотипические особенности течения гетерозиготной формы семейной гиперхолестеринемии у носителей мутаций генов LDLR и APOB. Кардиоваскулярная терапия и профилактика. 2011;10(8):63–65.
Burnett JR, Hooper AJ. Common and rare gene variants affecting plasma LDL cholesterol. Clin Biochem Rev. 2008 Feb;29(1):11–26. PMID: 18566665.
Мандельштам М. Ю, Васильев В. Б. Моногенные гиперхолестеринемии: новые гены, новые мишени для лечения. Генетика. 2008;44(10):1309–1316.
Шахтшнейдер Е. В., Иванощук Д. Е., Макаренкова К. В. и др. Каскадный генетический скрининг в диагностике гетерозиготной формы семейной гиперхолестеринемии: клинический случай. Российский кардиологический журнал 2017;146(6):178–179.
Abifadel M, Rabès JP, Devillers M et al. Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease. Hum Mutat. 2009 Apr;30(4):520–9. doi:10.1002/humu.20882
Ежов М. В., Бажан С. С., Ершова А. И. и др. Клинические рекомендации по семейной гиперхолестеринемии. Атеросклероз. 2019;15(1):58–98.
Wiegman A, Gidding SS, Watts GF et al. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J. 2015 Sep 21;36(36):2425–37. doi:10.1093/eurheartj/ehv157
Watts GF, Gidding S, Wierzbicki AS et al. Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation: executive summary. J Atheroscler Thromb. 2014;21(4):368–74. PMID: 24892180.
Marteau T, Senior V, Humphries SE et al. Psychological impact of genetic testing for familial hypercholesterolemia within a previously aware population: a randomized controlled trial. Am J Med Genet A. 2004 Jul 30;128A(3):285–93. doi:10.1002/ajmg.a.30102
Civeira F, Ros E, Jarauta E et al. Comparison of genetic versus clinical diagnosis in familial hypercholesterolemia. Am J Cardiol. 2008 Nov 1;102(9):1187–93, 1193.e1. doi:10.1016/j.amjcard.2008.06.056
Palacios L, Grandoso L, Cuevas N, et al. Molecular characterization of familial hypercholesterolemia in Spain. Atherosclerosis. 2012 Mar;221(1):137–42. doi:10.1016/j.atherosclerosis.2011.12.021
Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, Benetos A, Biffi A, Boavida JM, Capodanno D, Cosyns B, Crawford C, Davos CH, Desormais I, Di Angelantonio E, Franco OH, Halvorsen S, Hobbs FDR, Hollander M, Jankowska EA, Michal M, Sacco S, Sattar N, Tokgozoglu L, Tonstad S, Tsioufis KP, van Dis I, van Gelder IC, Wanner C, Williams B; ESC National Cardiac Societies; ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021 Sep 7;42(34):3227–3337. doi:10.1093/eurheartj/ehab484
Oscarsson J, Önnerhag K, Risérus U, Sundén M, Johansson L, Jansson PA, Moris L, Nilsson PM, Eriksson JW, Lind L. Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease: A double-blind, randomized, placebo-controlled study. J Clin Lipidol. 2018 Nov-Dec;12(6):1390–1403.e4. doi:10.1016/j.jacl.2018.08.003. Epub 2018 Aug 10. PMID: 30197273.
Wang X, Wen D, Chen Y, Ma L, You C. PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis. Cardiovasc Diabetol. 2022 Jun 15;21(1):107. doi:10.1186/s12933-022-01542-4. PMID: 35706032; PMCID: PMC9202167.
Lee J, Egolum U, Parihar H, Cooley M, Ling H. Effect of Ezetimibe Added to High-Intensity Statin Therapy on Low-Density Lipoprotein Cholesterol Levels: A Meta-Analysis. Cardiol Res. 2021 Apr;12(2):98–108. doi:10.14740/cr1224. Epub 2021 Feb 23. PMID: 33738013; PMCID: PMC7935639.
Banach M, Burchardt P, Chlebus K et al. PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021. Archives of Medical Science. 2021;17(6):1447–1547. doi:10.5114/aoms/141941
Ray KK, Reeskamp LF, Laufs U, Banach M, Mach F, Tokgözoğlu LS, Connolly DL, Gerrits AJ, Stroes ESG, Masana L, Kastelein JJP. Combination lipid-lowering therapy as first-line strategy in very high-risk patients. Eur Heart J. 2022 Feb 22;43(8):830–833. doi:10.1093/eurheartj/ehab718. PMID: 34636884.
Burnett H, Fahrbach K, Cichewicz A, Jindal R, Tarpey J, Durand A, Di Domenico M, Reichelt A, Viljoen A. Comparative efficacy of non-statin lipid-lowering therapies in patients with hypercholesterolemia at increased cardiovascular risk: a network meta-analysis. Curr Med Res Opin. 2022 May;38(5):777–784. doi:10.1080/03007995.2022.2049164. Epub 2022 Mar 20. PMID: 35262430.
Zhu L, Hayen A, Bell KJL. Legacy effect of fibrate add-on therapy in diabetic patients with dyslipidemia: a secondary analysis of the ACCORDION study. Cardiovasc Diabetol. 2020 Mar 5;19(1):28. doi:10.1186/s12933-020-01002-x. PMID: 32138746; PMCID: PMC7059389.
Blonde L, Umpierrez GE, Reddy SS, McGill JB, Berga SL, Bush M, Chandrasekaran S, DeFronzo RA, Einhorn D, Galindo RJ, Gardner TW, Garg R, Garvey WT, Hirsch IB, Hurley DL, Izuora K, Kosiborod M, Olson D, Patel SB, Pop-Busui R, Sadhu AR, Samson SL, Stec C, Tamborlane WV Jr, Tuttle KR, Twining C, Vella A, Vellanki P, Weber SL. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. Endocr Pract. 2022 Oct;28(10):923–1049. doi:10.1016/j.eprac.2022.08.002. Epub 2022 Aug 11. PMID: 35963508.
Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, Bisch JA, Richardson T, Jaros M, Wijngaard PLJ, Kastelein JJP; ORION-10 and ORION-11 Investigators. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med. 2020 Apr 16;382(16):1507–1519. doi:10.1056/NEJMoa1912387. Epub 2020 Mar 18. PMID: 32187462.
Raal FJ, Kallend D, Ray KK, Turner T, Koenig W, Wright RS, Wijngaard PLJ, Curcio D, Jaros MJ, Leiter LA, Kastelein JJP; ORION-9 Investigators. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. N Engl J Med. 2020 Apr 16;382(16):1520–1530. doi:10.1056/NEJMoa1913805. Epub 2020 Mar 18. PMID: 32197277.
Khan SA, Naz A, Qamar Masood M, Shah R. Meta-Analysis of Inclisiran for the Treatment of Hypercholesterolemia. Am J Cardiol. 2020 Nov 1;134:69–73. doi:10.1016/j.amjcard.2020.08.018. Epub 2020 Aug 15. PMID: 32892993.
Klebs S, Lecocq J, Mann С et al. Characterization of Inclisiran Use in Real World: Prescription Data from Germany. Journal og clinical lipidology 2022;16(3): Suppl e73; https://doi.org/10.1016/j.jacl.2022.05.060
SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe // European heart journal. 2021. Vol. 42. №. 25. P. 2439–2454.
Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Covington AM, DePalma SM, Minissian MB, Orringer CE, Smith SC Jr, Waring AA, Wilkins JT. 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2022 Oct 4;80(14):1366–1418. doi:10.1016/j.jacc.2022.07.006
Балахонова Т.В., Ершова А.И., Ежов М.В., Барбараш О. Л., Берштейн Л. Л., Богачев В. Ю., Воевода М. И., Генкель В.В., Гуревич В.С., Дупляков Д.В., Имаев Т.Э., Коновалов Г.А., Космачева Е. Д., Лобастов К.В., Митькова М. Д., Никифоров В. С., Ротарь О.П., Сучков И.А., Явелов И.С., Митьков В.В., Акчурин Р.С., Драпкина О.М., Бойцов С.А. Фокусированное ультразвуковое исследование сосудов. Консенсус российских экспертов. Кардиоваскулярная терапия и профилактика. 2022;21(7):3333. doi:10.15829/1728-8800-2022-3333. EDN WLJEHZ
Ершова А. И., Балахонова Т.В., Мешков А. Н., Куценко В. А., Яровая Е.Б., Шальнова С. А., Лищенко Н. Е., Новикова А. С., Александрова Е. Л., Шутемова Е. А., Белова О. А., Рачкова С. А., Бойцов С. А., Драпкина О. М. Распространенность атеросклероза сонных и бедренных артерий среди населения Ивановской области: исследование АТЕРОГЕН-Иваново. Кардиоваскулярная терапия и профилактика. 2021;20(5):2994.doi:10.15829/1728-8800-2021-2994.
Ershova A., Balakhonova T., Meshkov A., Kutsenko V., Belova O., Rachkova S., Shutemova E., Shalnova S., Boytsov S., Drapkina O. Carotid and femoral artery plaques as predictors of cardiovascular and all-cause mortality in the middle-aged general population. Atherosclerosis Supplements. 2022;355:e43–e44. DOI:https://doi.org/10.1016/j.atherosclerosis.2022.06.212.